314 related articles for article (PubMed ID: 34509737)
1. Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada.
Young S; Hayashi K; Grant C; Milloy MJ; DeBeck K; Wood E; Fairbairn N
Drug Alcohol Depend; 2021 Nov; 228():109006. PubMed ID: 34509737
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
3. The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting.
Mackay L; Kerr T; Fairbairn N; Grant C; Milloy MJ; Hayashi K
Addict Sci Clin Pract; 2021 Apr; 16(1):26. PubMed ID: 33910630
[TBL] [Abstract][Full Text] [Related]
4. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
[TBL] [Abstract][Full Text] [Related]
5. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
[TBL] [Abstract][Full Text] [Related]
6. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
Shearer D; Young S; Fairbairn N; Brar R
Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
[TBL] [Abstract][Full Text] [Related]
7. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
[TBL] [Abstract][Full Text] [Related]
8. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
9. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
10. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Bastien G; McAnulty C; Ledjiar O; Socias ME; Le Foll B; Lim R; Hassan AN; Brissette S; Marsan S; Talbot A; Jutras-Aswad D;
Can J Psychiatry; 2023 Aug; 68(8):572-585. PubMed ID: 36519188
[TBL] [Abstract][Full Text] [Related]
11. Short term health-related quality of life improvement during opioid agonist treatment.
Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
[TBL] [Abstract][Full Text] [Related]
12. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
14. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
Weicker SA; Hayashi K; Grant C; Milloy MJ; Wood E; Kerr T
Drug Alcohol Depend; 2019 Dec; 205():107672. PubMed ID: 31706251
[TBL] [Abstract][Full Text] [Related]
15. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
16. Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada.
Pilarinos A; Kwa Y; Joe R; Thulien M; Buxton JA; DeBeck K; Fast D
Int J Drug Policy; 2022 Sep; 107():103773. PubMed ID: 35780565
[TBL] [Abstract][Full Text] [Related]
17. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
Bozinoff N; DeBeck K; Milloy MJ; Nosova E; Fairbairn N; Wood E; Hayashi K
Drug Alcohol Depend; 2018 Dec; 193():42-47. PubMed ID: 30340144
[TBL] [Abstract][Full Text] [Related]
18. Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada.
Iacono A; Wang T; Tadrous M; Campbell T; Kolla G; Leece P; Sproule B; Kleinman RA; Besharah J; Munro C; Doolittle M; Gomes T
Drug Alcohol Depend; 2024 Jan; 254():111032. PubMed ID: 38043224
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
20. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
Brothers TD; Fraser J; MacAdam E; Morgan B; Webster D
Drug Alcohol Rev; 2022 Feb; 41(2):430-434. PubMed ID: 34347327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]